Baseline characteristics
| Infliximab (n = 6) | Placebo (n = 6) | |
|---|---|---|
| *n = 5. | ||
| DAS, Disease Activity Score; VAS, visual analogue scale; CRP, C reactive protein; PASI, Psoriasis Area and Severity Index; MTX, methotrexate. | ||
| Results are shown as mean (range). | ||
| Age | 53 (35–70) | 45 (26–60) |
| Male: female | 3:3 | 3:3 |
| Duration of joint disease (years) | 9 (5–13)* | 9 (1–22) |
| Duration of skin disease (years) | 24 (10–41) | 17 (2–38)* |
| DAS | 6.8 (5.0–7.9)* | 5.7 (4.8–8.2) |
| 30 Tender joint count | 19 (2–26)* | 9 (2–25) |
| 30 Swollen joint count | 15 (9–21)* | 7 (2–26) |
| VAS | 81 (65–90)* | 68 (36–93) |
| CRP | 23 (10–36)* | 28 (7–65) |
| PASI | 13.7 (1–29.8) | 10.5 (5–19.0)* |
| MTX dose (mg/week) | 10 (5–20) | 10 (5–20) |